Henlius Says ASTRIDE Trial Shows Favorable Survival for Serplulimax
Shanghai Henlius Biotech reports that its ASTRIDE trial showed favorable median overall survival for serplulimax versus atezolizumab.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.